PMID- 33628325
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210226
IS  - 1741-427X (Print)
IS  - 1741-4288 (Electronic)
IS  - 1741-427X (Linking)
VI  - 2021
DP  - 2021
TI  - ChaiQi Decoction Alleviates Vascular Endothelial Injury by Downregulating the 
      Inflammatory Response in ApoE-Model Mice.
PG  - 9415819
LID - 10.1155/2021/9415819 [doi]
LID - 9415819
AB  - Metabolic syndrome (MetS) is a pathological state of metabolic disorders that 
      primarily occur in human proteins, fats, and carbohydrates. It is a complex 
      cluster of core metabolic disorder syndromes including obesity, hyperglycemia, 
      dyslipidemia, and hypertension, and vascular endothelial injury, occurring over 
      time. The currently available treatment options cannot effectively manage MetS. 
      In our previous research, we revealed ChaiQi decoction (CQD) as an effective 
      prescription for improving MetS; however, the specific mechanism remains unclear. 
      Herein, we assessed the efficacy and mechanism of CQD in ApoE gene knockout 
      (ApoE-) mice. Mice were administered with CQD daily for 12 weeks, and the 
      measurement of their body weight was taken monthly. To evaluate the metabolic 
      levels of mice, we determined the fasting blood glucose (FBG), fasting serum 
      insulin (FINS), insulin resistance index (IRI), triglyceride (TG), total 
      cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and low-density 
      lipoprotein cholesterol (LDL-C) levels. Furthermore, immunohistochemical analysis 
      was adopted to determine the expression of ICAM-1 and VCAM-1 in vascular 
      endothelium, while an optical microscope was adopted to observe the pathological 
      morphology of abdominal aorta in mice. Tumor necrosis factor-alpha (TNF-alpha), 
      interleukin-6 (IL-6), intercellular cell adhesion molecule-1 (ICAM-1), and 
      vascular cell adhesion molecule-1 (VCAM-1) levels were determined using the ELISA 
      method, whereas Western blotting was used to determine nuclear factor- (NF-) kappaB 
      p65. Of note, intragastric CQD administration ameliorated ApoE-model mice, as 
      evidenced by reduced levels of FBG, FINS, IRI, TG, TC, and LDL-C. Furthermore, 
      CQD alleviated vascular endothelial injury and regularized the structure of the 
      abdominal aorta by downregulating the expressions of proinflammatory cytokines 
      TNF-alpha, IL-6, ICAM-1, VCAM-1, and NF-kappaB p65. Overall, these findings advocated 
      that CQD ameliorates metabolic levels and vascular endothelial injury in mice by 
      downregulating the inflammatory response and thus may be utilized as a novel MetS 
      therapy.
CI  - Copyright (c) 2021 Bingran Wang et al.
FAU - Wang, Bingran
AU  - Wang B
AUID- ORCID: 0000-0002-2955-2760
AD  - Graduate School, Beijing University of Chinese Medicine, Beijing, China.
AD  - Department of Gastroenterology, Dongfang Hospital, Beijing University of Chinese 
      Medicine, Beijing, China.
FAU - Zhang, Jiayan
AU  - Zhang J
AD  - Department of Gastroenterology, Dongfang Hospital, Beijing University of Chinese 
      Medicine, Beijing, China.
FAU - Lu, Yuhong
AU  - Lu Y
AD  - Graduate School, Beijing University of Chinese Medicine, Beijing, China.
FAU - Peng, Long
AU  - Peng L
AD  - Graduate School, Beijing University of Chinese Medicine, Beijing, China.
AD  - Department of Gastroenterology, Dongfang Hospital, Beijing University of Chinese 
      Medicine, Beijing, China.
FAU - Yuan, Wenling
AU  - Yuan W
AD  - Graduate School, Beijing University of Chinese Medicine, Beijing, China.
AD  - Department of Gastroenterology, Dongfang Hospital, Beijing University of Chinese 
      Medicine, Beijing, China.
FAU - Zhao, Yuqing
AU  - Zhao Y
AD  - Graduate School, Beijing University of Chinese Medicine, Beijing, China.
AD  - Department of Gastroenterology, Dongfang Hospital, Beijing University of Chinese 
      Medicine, Beijing, China.
FAU - Zhang, Liping
AU  - Zhang L
AUID- ORCID: 0000-0001-6419-4391
AD  - Graduate School, Beijing University of Chinese Medicine, Beijing, China.
LA  - eng
PT  - Journal Article
DEP - 20210210
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
PMC - PMC7889348
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2021/02/26 06:00
MHDA- 2021/02/26 06:01
PMCR- 2021/02/10
CRDT- 2021/02/25 05:45
PHST- 2020/07/19 00:00 [received]
PHST- 2020/12/29 00:00 [revised]
PHST- 2021/01/09 00:00 [accepted]
PHST- 2021/02/25 05:45 [entrez]
PHST- 2021/02/26 06:00 [pubmed]
PHST- 2021/02/26 06:01 [medline]
PHST- 2021/02/10 00:00 [pmc-release]
AID - 10.1155/2021/9415819 [doi]
PST - epublish
SO  - Evid Based Complement Alternat Med. 2021 Feb 10;2021:9415819. doi: 
      10.1155/2021/9415819. eCollection 2021.